CSL
CSL Limited is an Australian global biotechnology company specializing in plasma-derived therapies, vaccines, and iron deficiency treatments. The enterprise operates through three core business segments: CSL Behring, CSL Seqirus, and CSL Vifor. Its product portfolio includes plasma therapies for rare diseases, cell-based influenza vaccines, recombinant coagulation factors, and iron management pharmaceuticals. Revenue is driven by product distribution to healthcare providers, hospitals, and government immunization programs worldwide. The company holds a market-leading global position in plasma collection, immunoglobulin manufacturing, and influenza prevention. CSL Limited is headquartered in Melbourne, Australia, and listed on the Australian Securities Exchange.
34 of the funds FundTelligence covers report a position in CSL.
- Legal name
- CSL Ltd
- Sector
- Health Care
- Country
- Australia
- Funds holding it
- 34
Funds holding CSL
- iShares Pacific Index Fund (IE) — BlackRock · 2.78 % (largest positions only, September 2026)
- Lannebo Marknad Pacific — Lannebo · 2.54 % (full portfolio disclosed, June 2026)
- DWS Invest CROCI Global Dividends — DWS · 2.26 % (full portfolio disclosed, June 2026)
- Fidelity FIRST All Country World Fund — Fidelity · 2.1 % (largest positions only, October 2026)
- PriorNilsson Globala Utdelare — PriorNilsson · 1.26 % (full portfolio disclosed, June 2026)
- DWS Invest CROCI World Value — DWS · 1.05 % (full portfolio disclosed, June 2026)
- Danske Invest Index Pacific incl. Canada ex. Japan Restricted — Danske Invest · 0.77 % (full portfolio disclosed, July 2026)
- KLP AksjeAsia Indeks — KLP · 0.53 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 34 funds holding it.